Arch Biopartners is developing next-generation drug candidates that target IL-32, a cytokine implicated in diabetic kidney disease as described in Dr. Chun’s new publication. The goal is to produce a ...

Sanofi’s work with engineered cytokines has stumbled in the clinic, but the company isn’t throwing in the towel yet on such therapies, which hold potential for treating autoimmune diseases and cancer.

Please provide your email address to receive an email when new articles are posted on . The excessive production of proinflammatory cytokines may drive the symptoms of long COVID due to a genetic ...

CAR T-cell therapy results in a high incidence of cytokine release syndrome, but it is manageable in most cases. The review, encompassing 19 studies, reveals a high incidence of CRS in patients with ...

No potential conflict of interest relevant to this letter was reported. Gaestel M. What goes up must come down: molecular basis of MAPKAP kinase 2/3-dependent regulation of the inflammatory response ...

Autoimmune diseases result from a complex interaction of immune system imbalances, marked by a breakdown in self-tolerance and sustained inflammation. At the core of this dysregulation are ...

Cancer is considered a significant public health issue worldwide. Several fundamental studies and clinical trials have displayed that immunotherapy is one of the most efficient and hopeful therapeutic ...

It can be a relief to scratch the occasional itch, but when an itch gets out of control and doesn’t stop it can become a serious health problem. Scientists at the University of California, San ...

Lipid nanoparticle (LNP) mRNA vaccines induce robust immune responses and provide protection against infectious diseases. However, this immunity can be short-lived, resulting in the need for frequent ...